Definium Therapeutics, Inc. (MNMD)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
MNMD has surged 101% in six months with MM120 advancing in phase III for GAD and MDD. Pivotal readouts are slated for 2026.
Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript
Mind Medicine (MindMed) Inc. ( MNMD ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Robert Barrow - CEO & Director Daniel Karlin - Chief Medical Officer Brandi Roberts - Chief Financial Officer Conference Call Participants Yesha Patel - Evercore ISI Institutional Equities, Research Division Sarah Medeiros - Cantor Fitzgerald & Co., Research Division Matthew Hershenhorn - Oppenheimer & Co. Inc., Research Division François Brisebois - LifeSci Capital, LLC Ami Fadia - Needham & Company, LLC, Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Christopher Chen - Robert W.
MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy
Mind Medicine (MNMD) is advancing its lead drug MM120 through Phase 3 trials for anxiety and depression, positioning for long-term upside. MNMD's strong cash reserves, disciplined spending, and extended debt flexibility provide a comfortable runway into 2027, supporting ongoing clinical programs. The company targets a $25 billion addressable market, with MM120 aiming to disrupt current standard-of-care treatments for generalized anxiety disorder.
Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Brandi L. Roberts - Chief Financial Officer Daniel Rollings Karlin - Chief Medical Officer Matthew Wiley - Chief Commercial Officer Robert Barrow - CEO & Director Stephanie Fagan - Chief Corporate Affairs Officer Conference Call Participants Brian Corey Abrahams - RBC Capital Markets Christopher W.
All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy
Mind Medicine MindMed (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade
The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 237.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?
The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 279.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin - CMO Conference Call Participants Madhu Yennawar - Leerink Gavin Clark-Gartner - Evercore ISI Charles Duncan - Cantor Joel Beatty - Baird Rudy Li - Chardan Sumant Kulkarni - Canaccord Genuity Patrick Trucchio - HC Wainwright & Company Michael Okunewitch - Maxim Group Operator Good morning, and welcome to the Mind Medicine Fourth Quarter and Year-End 2024 Financial Results Corporate Update Conference Call. Currently, all participants are in listen-only mode.
Why Mind Medicine Stock Is Skyrocketing Today
Mind Medicine (MNMD 15.66%) stock is seeing impressive gains Friday. The company's share price was up 16.9% as of 3:15 p.m.
Why Mind Medicine Stock Is Soaring Today
Mind Medicine (MNMD 8.97%) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% as of 2 p.m.
MindMed Stock Skyrockets 94% Year to Date: What's Driving It?
2024 was a transformational year for MNMD as it executed many important milestones.
